Picture1.jpg
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
June 17, 2024 08:51 ET | Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Picture1.jpg
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
June 17, 2024 08:51 ET | Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Picture1.jpg
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
June 05, 2024 05:27 ET | Curium
Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
Picture1.jpg
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
May 30, 2024 03:00 ET | Curium US LLC
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
Curium
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024 03:32 ET | Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Picture1.jpg
Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs
May 06, 2024 04:25 ET | Curium
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
Picture1.jpg
Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
May 06, 2024 04:25 ET | Curium
Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
Picture1.jpg
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
April 23, 2024 00:01 ET | Curium
patient enrollment in clinical trial
Picture1.jpg
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
April 09, 2024 08:50 ET | Curium
Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE